<DOC>
	<DOCNO>NCT00329589</DOCNO>
	<brief_summary>The purpose study determine safety Velcade use chemoradiation cancer patient .</brief_summary>
	<brief_title>A Trial Using Velcade Plus Chemoradiation Central Nervous System , Head Neck , Cervical Cancer Patients</brief_title>
	<detailed_description>- To determine maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) Velcade® administer twice weekly 3-5 second IV bolus every 3 week patient malignancy brain , head neck cervix receive 2-8 week chemoradiation . - To evaluate safety toxicity profile Velcade® administer twice weekly ( day 1 , 4 , 8 11 ) every 3 week ( maximum 8 week ) concurrent chemoradiation . - To evaluate tumor response</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm malignancy Requiring least grade 2 week radiation therapy Solid tumor central nervous system , head neck area , cervix World Health Organization ( WHO ) performance status equal le 2 Equal great grade 2 peripheral neuropathy Myocardial infarction within 6 month Hypersensitivity bortezomib , boron , mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Malignancies central nervous system , head neck area</keyword>
	<keyword>cervix</keyword>
</DOC>